Keywords: Multiple sclerosis; Pharmaceutical reimbursement, Decision-making; CHMP; committee for medicinal for human use; ICER; incremental cost-effectiveness ratio; MCID; minimal clinically important difference; MS; multiple sclerosis; PBAC; pharmaceutical benefit
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: European regulation model; HMP; EU monograph; TUR; WEU-MA; ESCOP; European Scientific Cooperative on Phytotherapy; WHO; World Health Organization; EU; European Union; HMPs; herbal medicinal products; WEU-MAs; marketing authorizations; TURs; traditional us
Keywords: ADA; anti-drug antibodies; CHMP; Committee for Medicinal Products for Human Use; DIN; Drug Identification Number; ECCO; European Crohn's and Colitis Organisation; EMA; European Medicines Agency; FDA; Food and Drug Administration; INN; International Nonp
Keywords: Cytokinesis; Centralspindlin; Anillin; ESCRT complex; Abscission; ALIX; apoptosis-linked gene-2 interacting protein X; ANCHR; abscission/NoCut Checkpoint Regulator; CHMP; charged multivesicular body protein; CPC; chromosome passenger complex; ESCRT; Endos
Keywords: Advanced therapy medicinal products; Cell therapy; Clinical trials regulation; Committee for Advanced Therapies; European Medicines Agency; Marketing authorisation application; ATMP; advanced therapy medicinal products; CAT; Committee for Advanced Therapi
Keywords: Cell therapy; Minimally manipulated; Homologous use; Health Canada; Food and Drugs Act; Food and Drug Regulations; AHR Act; Assisted Human Reproduction Act of Canada; BGTD; Biologics and Genetic Therapies Directorate; CBER; Center for Biologics Evaluation
Keywords: CFR; Code of Federal Regulations; CHMP; Committee for Medicinal Products for Human Use; COMP; Committee for Orphan Medicinal Products; EC; European Commission; EMA; European Medicines Agency; EU; European Union; FDA; Food and Drug Administration; MHLW; Mi
Keywords: ID; intradermal; SC; subcutaneous; HA; hemagglutinin; HAI; hemagglutination inhibition; NT; microneutralization; GMT; geometrical mean titer; GMTR; GMT ratio; SCR; seroconversion ratio; SPR; seroprotection ratio; AE; adverse event; CHMP; The Committee for
Keywords: SCIT; Subcutaneous Immunotherapy; EFSA; The European Food Safety Authority; TWI; Tolerable Weekly Intake; CHMP; Committee for Medical Products for Human use; EMA; European Medicine Agency; PDCO; The Paediatric Committee; MPL; Monophosphoryl Lipid A; PEI;
Keywords: ADA-SCID; adenosine deaminase deficiency; cDNA; complementary DNA; CHMP; Committee on Human Medicinal Products; DHFR; dihydrofolate reductase; DNA; deoxyribonucleic acid; E1; adenoviral gene; E1B 55K; adenoviral gene; EMA; European Medicines Agency; FDA;
Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges
Keywords: ACR; American College of Rheumatology; ADAb; anti-drug antibody; ADCC; antibody-dependent cell-mediated cytotoxicity; AIFA; Italian Medicines Agency; CDC; complement-dependent cytotoxicity; CHMP; Committee for Medicinal Products for Human Use; DAS28; 28-j
ESCRT genes and regulation of developmental signaling
Keywords: ABA; abscisic acid; AUX1; AUXIN-RESISTANT1; CHMP; charged multivesicular body protein; Crb; crumbs; DSL; delta/serrate/lag-2; Dx; Deltex; Dome; domeless; Dpp; decapentaplegic; EGFR; epidermal growth factor receptor; ESCRT; endosomal sorting complex requir
The role of ESCRT during development and functioning of the nervous system
Keywords: ALIX; CHMP; Synapse; Cortex development;
Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments
Keywords: ACR; American College of Radiology; AD; Alzheimer disease; ADNI; Alzheimer's Disease Neuroimaging Initiative; ALS; Amyotrophic Lateral Sclerosis; ASD; Autism Spectrum Disorder; BBB; Blood-Brain-Barrier; BEST; Biomarkers, Endpoints and other Tools; BLA; Bi
Finding synergies for 3Rs - Toxicokinetics and read-across: Report from an EPAA partners' Forum
Keywords: Physiologically-based kinetic (PBK) modelling; Hazard and risk assessment; Weight-of-evidence (WoE); Threshold of toxicological concern (TTC); In vitro to in vivo extrapolation (IVIVE); Integrated approach for testing and assessment (IATA); Absorption; Di
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial
Keywords: AE; adverse event; AESI; adverse event of specific interest; AS; adjuvant system; CBER; Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; EMA; European Medicines Agency; GMT; geome
Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial
Keywords: AE; adverse event; CBER; Center for Biologics Evaluation and Research; CHMP; Committee for Medical Products for Human Use; CI; confidence interval; GMT; geometric mean titers; HA; hemagglutinin; HI; hemagglutination-inhibition; MGI; mean geometric increas
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union
Keywords: Biosimilar insulin; Glucodynamics; Insulin glargine; Nonclinical; Pharmacokinetics; Pharmacology; Preclinical; Rats; Toxicology; ANOVA; analysis of variance; AUC0-24hr; exposure over 24-hour period; BHI; biosynthetic human insulin; CHMP; Committee on Me
Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective
Keywords: EU; European Union; MA; marketing authorisation; BE; bioequivalence; BCS; Biopharmaceutics Classification System (BCS); CHMP; Committee for Medicinal Products for Human Use; NHS; National Health System; API; active pharmaceutical ingredient; EMA; European
Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction
Keywords: AUC; area under the plasma concentration-time curve; CHMP; Committee for Medicinal Products for Human Use; EGFR; epidermal growth factor receptor; FDA; Food and Drug Administration; FVB; Friend Leukemia Virus; HER; human epidermal growth-factor receptor
Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries
Keywords: Regulatory requirements; Biosimilars; Labelling survey; Physician preference; ASBM; Alliance for Safe Biologic Medicines; CHMP; Committee for Medicinal Products for Human Use; EMA; European Medicines Agency; EPAR; European Public Assessment Report; GaBI;
NMR Reveals the Interplay among the AMSH SH3 Binding Motif, STAM2, and Lys63-Linked Diubiquitin
Keywords: AMSH; associated molecule with the SH3 domain of STAM; AMSH-LP; AMSH-like protein; AMSH-SBM; SBM motif of AMSH; CHMP; charged multivesicular body proteins; CSP; chemical shift perturbation; ESCRT; endosomal sorting complexes required for transport; Hrs; h
Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults
Keywords: aIIV3; adjuvanted trivalent inactivated influenza vaccine; IIV3; inactivated trivalent influenza vaccine; PPSV23; 23-valent pneumococcal polysaccharide vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; HI; hemagglutination inhibition; GMT; geometr
Contribución de la Agencia Española de Medicamentos y Productos Sanitarios al Comité Europeo de Evaluación de Medicamentos de Uso Humano
Keywords: AEMPS; CHMP; EMA; Medicamentos de uso humano; Procedimiento centralizadoAEMPS; CHMP; EMA; Medicinal products for human use; Centralized procedure
Contribution of the Spanish Agency for Medicines and Healthcare Products to the European Committee for the Evaluation of Medicinal Products for Human Use
Keywords: AEMPS; CHMP; EMA; Medicinal products for human use; Centralized procedureAEMPS; CHMP; EMA; Medicamentos de uso humano; Procedimiento centralizado
Les médicaments orphelins : des opportunités méconnues pour les développeurs en Europe
Keywords: Orphan Drug Act; règlement 141/2000/CE; règlement d'éxécution 847/2000; Communication de la Commission (2003/C 178/02); médicaments orphelins; exclusivité commerciale de 10 ans; médicaments similaires; bénéfice notable; supériorité clinique;
Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years
Keywords: AEs; adverse events; CBER; US Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CIs; confidence intervals; GMTs; geometric mean titers; HA; hemagglutinin antigen; HI; hemagglutination-inhibition; MAEs; med
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: A phase IV, randomized, open-label, controlled study
Keywords: AS03; H5N1 vaccine; Pandemic influenza; Korean adults; AEs; adverse events; CBER; US Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; EMA; European Medicines Agency; FDA; US Food
RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap
Keywords: CHMP; Committee for Medicinal Products for Human Use; CSP; circumsporozoite protein; EMA; European Medicines Agency; GFATM; Global Fund to Fight Aids, Tuberculosis and Malaria; HBsAg; hepatitis B virus surface antigen; ITT; intention-to-treat; JTEG; Joint
Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study
Keywords: ID; intradermal; SC; subcutaneous; HA; hemagglutinin; HAI; hemagglutination inhibition; GMT; geometrical mean titer; GMTR; ratio of GMT; SCR; seroconversion ratio; SPR; seroprotection ratio; AE; adverse event; CHMP; The Committee for Medicinal Products fo
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects
Keywords: Influenza vaccine; MF59; Adjuvant; Non-inferiority; Superiority; Elderly; AE; adverse event; aTIV; adjuvanted trivalent influenza vaccine; CBER; Center for Biologics Evaluation and Research; CHMP; European Committee for Medicinal Products for Human Use; F
An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age
Keywords: AEs; adverse events; CBER; Center for Biologics Evaluation & Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; GMFR; geometric mean fold rise; GMT; geometric mean titer; HA; hemagglutinin; HI; hemagglutination inhibi
Elimination pathways of cyclosarin (GF) mediated by β-cyclodextrin in vitro: Pharmacokinetic and toxicokinetic aspects
Keywords: CD; cyclodextrin; β-CD; β-cyclodextrin; OP; organophosphorus compound(s); GF; cyclosarin; ESI/MS; electrospray ionization mass spectrometry; CHMPA; O-cyclohexylmethylphosphonic acid; CHMP; O-cyclohexylmethylphosphonate; TRIS; tris(hydroxymethyl)aminomet
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial
Keywords: ATP; according to protocol; BARDA; Biomedical Advanced Research and Development Authority; BMI; body mass index; CBER; Center for Biologics Evaluation & Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; GMFR; geometr
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations
Keywords: MN; microneutralisation; HI; haemagglutination inhibition; CHMP; European Committee for Medicinal Products for Human Use; AE; adverse event; SAE; serious adverse event; GMR; geometric mean ratio; GMT; geometric mean titre; Influenza; H1N1; Pandemic; Adjuv
A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects
Keywords: HI; haemagglutination inhibition; MN; microneutralization; CHMP; European committee for medicinal products for human use; AE; adverse event; SAE; serious adverse event; GMR; geometric mean ratio; GMT; geometric mean titre; ANOVA; analysis of variance; SD;
A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic
Keywords: AE; adverse event; AESI; adverse event of special interest; CHMP; Committee for Medicinal Products for Human Use; EMA; European Medicines Agency; HLT; High Level Term; PT; Preferred Term; SAE; serious adverse event; SOC; System Organ Class; WHO; World Hea
Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials
Keywords: AE; adverse event; AS03; oil-in-water emulsion based adjuvant system; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; GMFR; geometric mean fold rise; GMT; geometric mean titre; GSK; GlaxoSmithKline; HA; haemagglutinin antige
AMSH is required to degrade ubiquitinated proteins in the central nervous system
Keywords: AD; Alzheimer's disease; ALS; amyotrophic lateral sclerosis; AMSH; associated molecule with the SH3 domain of STAM; AMPAR; α-amino-3-hydroxy-5-methyl-isoxazolepropionic acid receptor; CHMP; chromatin modifying protein; ESCRT; endosomal sorting complexe
Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector
Keywords: AE; adverse event; CBC; complete blood count; CDC; centers for Disease Control and Prevention; CHMP; Committee for Human Medicinal Products; CI; confidence interval; DSJI; disposable-syringe jet injection/injector; EMEA; European Medicines Agency; FDA; U.
Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: A prospective cohort study
Keywords: AEs; adverse events; AESI; adverse events of special interest; AS03; oil-in-water emulsion-based Adjuvant System AS03; CDC; Centers for Disease Control and Prevention; CHMP; Committee for Medicinal Products for Human Use; EGA; estimated gestational age; G
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents
Keywords: AE; adverse event; AS; Adjuvant System; AS03; tocopherol oil-in-water emulsion based Adjuvant System; ATP; according to protocol; BS; blood sampling; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; EMA; European Medicines Ag
Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants
Keywords: European Medicines Agency; EMEA; Committee for Medicinal Products for Human Use; CHMP; Antidepressants; Major depression; Drug evaluation
Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials
Keywords: AEFI; adverse events following immunisation; AlPO4; aluminium phosphate; Al(OH)3; aluminium hydroxide; CHMP; Committee for Human Medicinal Products; ECBS; Expert Committee on Biological Standardisation; HAI; haemagglutination-inhibition; LAIV; live-attenu
If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
Keywords: CHMP; Committee for Medicinal Products for Human Use; COX; Cycloxygenase; ECG; Electrocardiogram; EU; European Union; FDA; Food and Drug Administration of the United States; hERG; Human ether-a-go-go related gene; ICH; International Conference on Harmoniz
A systematic analysis of human CHMP protein interactions: Additional MIT domain-containing proteins bind to multiple components of the human ESCRT III complex
Keywords: Protein interaction network; Multivesicular bodies; ESCRT III complex; MIT domain; CHMP; Yeast two-hybrid; Protein complementation assay